NASH limits anti-tumour surveillance in immunotherapy-treated HCC

According to this article by D. Pfister et al. (German Cancer Research Center, Germany), the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH). This might be due to the amount or quality of viral antigens....
PUBLISHED IN: Nature 2021

Commentary

According to this article by D. Pfister et al. (German Cancer Research Center, Germany), the response to immunotherapy is better in patients with virus-induced HCC than in patients with non-viral HCC (that is, NASH). This might be due to the amount or quality of viral antigens or to a different liver micro-environment, possibly one that does not impair immune surveillance.

“These results might also have implications for patients with obesity and NALFD or NASH who have cancer at other organ sites”.

Share the article
Dr. D. Beard

Dr. D. Beard

Articles: 207

Leave a Reply

Your email address will not be published.